Combination targeted and immune therapy in the treatment of advanced melanoma: a valid treatment option for patients?

ABSTRACT: Melanomas harboring an activating BRAFV600 mutation account for 50% of all advanced melanomas. The approval of BRAF-targeted therapy revolutionized treatment of these patients with achievement of impressive responses. However, development of resistance to these drugs is a significant problem, and as such, duration of response remains low, with median progression free survival of around 11-15 months. Immune checkpoint blockers exploit the immune system to eradicate cancer and can produce durable disease control that results in long-term, treatment-free survival in some patients. These drugs have shown very impressive survival in patients with BRAF-mutated melanoma. Thus, there is a need to continue to utilize emerging data to achieve long-term disease control for patients with advanced mela

SUBMITTER: Bari S 

PROVIDER: S-EPMC9036333 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature